Announcements Trials

Browse Landscape

Phase

Status

Completed 15 Terminated 3 Withdrawn 1 Unknown 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Subcutaneous panniculitis-like T-cell lymphoma 1 Neoplasms 1 Lymphoma, T-Cell 1 Lymphoma, Primary Cutaneous Anaplastic Large Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Extranodal NK-T-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Immunoblastic Lymphadenopathy 1 Enteropathy-Associated T-Cell Lymphoma 1 Colorectal Adenocarcinoma 1 Cardiovascular Diseases 1 Breast Neoplasms 1 Bone Metabolism Biomarkers 1

Interventions

Paclitaxel 62 Letrozole 55 Fulvestrant 55 Trastuzumab 50 palbociclib 41 pembrolizumab 37 Cyclophosphamide 37 Carboplatin 37 Anastrozole 37 pertuzumab 35 exemestane 25 Tamoxifen 24 Capecitabine 24 ribociclib 23 abemaciclib 23 Radiotherapy 21 Docetaxel 21 olaparib 20 Doxorubicin 20 Magnetic Resonance Spectroscopy 19 trastuzumab deruxtecan 17 Surveys and Questionnaires 17 durvalumab 16 Epirubicin 16 Specimen Handling 14 Exercise 14 130-nm albumin-bound paclitaxel 14 Taxes 13 Alpelisib 13 Goserelin 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Breast Neoplasms × Cholecalciferol × Clear all

NCT04067726 2026-03-31

TRIDENT

Washington University School of Medicine

Phase 2 Active not recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡